A new report evaluating the economic impact of clinical trials conducted by research networks, was published this week by the Australian Clinical Trials Alliance (ACTA) and the Australian Commission on Safety and Quality in Healthcare (ACSQHC).
This report evolved after growing international evidence suggested that programs of high-quality investigator-initiated clinical trials have had a major impact on healthcare quality and outcomes. Until now, however, an evaluation to quantify the potential health and economic benefits generated by investigator-initiated clinical trials conducted in Australia had not been undertaken.
Whilst not a subject of this specific evaluation the Australasian Gastro Intestinal Trials Group (AGITG), is a well established clinical trials research network.
Clinical Trails Networks, like the AGITG, involve multiple healthcare facilities and practicing clinicians, and form in order to overcome some of the challenges of designing and conducting these trials successfully. The benefit of a network working collaboratively is that they ensure highly relevant research questions are generated and that the correct research methodology is used.
Clinical trials generate evidence to inform best-practice ways of providing care or treatment to patients and explore the impact of new or existing approaches to health care. The outcomes of clinical trials can provide evidence that leads to the adoption or continuation of effective treatment and care, or the cessation of ineffective interventions.
A key finding from the ACSQHC report is that there would be gross benefits of $2 billion if the results of 25 specific high-impact, investigator-initiated clinical trials were implemented in just two thirds (65%) of the eligible Australian population for just one year.
The report has also shown that for every $1 awarded in National Health and Medical Research Council (NHMRC) grants to the 25 trials, a return of $51.10 was achieved and that just 9% of the $2 billion gross benefit was equivalent to all NHMRC funding received by all Australian networks between 2004 and 2014.
The report also highlights the potential of well-designed clinical trials to lead to improvements in healthcare quality through the adoption or continuation of effective treatment and care, or the cessation of ineffective interventions.
As has been demonstrated through the AGITG, trials conducted by networks influence clinical guidelines, identify ways to improve safety and quality and identify opportunities for more efficient resource use. This report helps to confirm that increasing the implementation of trial evidence into practice can lead to considerable additional health and economic gains.
For more please see – https://www.safetyandquality.gov.au/our-wo…/clinical-trials/